1. Introduction {#sec1}
===============

Janus kinase (JAK) inhibitors, such as ruxolitinib(INCB018424), are being widely used for their excellent efficacy in decreasing the constitutional symptoms and splenomegaly in patients with myeloproliferative neoplasms such as primary myelofibrosis (MF) \[[@B1]\]. The JAK-STAT (signal inducer and activator of transcription) pathway is essential for host immunity and defense \[[@B2], [@B3]\]. Clinical trials of ruxolitinib have not shown a significant increase in infectious complications \[[@B4]\]. However, several case reports have been published recently describing opportunistic infections in patients on treatment with ruxolitinib \[[@B5]--[@B15]\]. We report a case of reactivation pulmonary tuberculosis (TB) following ruxolitinib therapy.

2. Case {#sec2}
=======

A 69-year-old male, retired physician who practiced in India was diagnosed with primary myelofibrosis in May 2015. His initial presentation included anemia with massive splenomegaly. Spleen size was evaluated by USS and measured 28 cm in long axis. Constitutional symptoms at diagnosis included night sweats, abdominal pain, weight loss, itching, fatigue, and early satiety. His medical history was negative for major infectious disease. Bone marrow biopsy confirmed MF, grade MF 3 \[[@B16]\], JAK2V617F mutation negative, MPL exon 10 mutation negative, and CALR mutation positive. This was a type 1 mutation with 52 bp deletion in exon 9 of CALR gene.

He had an intermediate 2 DIPSS plus score and was started on ruxolitinib at 20 mg twice daily for symptom relief. He had a rapid improvement in his constitutional symptoms in the first three weeks of treatment with ruxolitinib. Prior to receipt of ruxolitinib, a screening chest X-ray was negative. Three weeks after initiation of ruxolitinib therapy, he was admitted to the hospital with high-grade fevers (*T* ~max~ 102°F), night sweats, shortness of breath, and nonproductive cough. His physical exam revealed matted cervical lymphadenopathy and splenomegaly. QuantiFERON-TB test (Celestis, Valencia, CA) was positive. Computed tomography (CT) of the chest showed bilateral lung nodules, left sided pleural effusion, and lower cervical and mediastinal conglomerate adenopathy ([Figure 1](#fig1){ref-type="fig"}). An excisional lymph node biopsy of a cervical node showed necrotizing granulomatous inflammation and rare acid-fast bacilli (AFB) (see Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Lymph node tissue cultures were positive for*Mycobacterium tuberculosis*complex by gene-probe (GenProbe, San Diego, CA). Ruxolitinib was discontinued and standard 9-month four-drug antituberculosis therapy (ATT) with rifampin, isoniazid, pyrimethamine, and ethambutol was started which led to rapid improvement in his symptoms. After 6 months of successful ATT, ruxolitinib was reintroduced for his MF symptoms, and he was continued on ATT with isoniazid and rifampin. At follow-up, he remains without transfusion needs and is symptomatically improved with minimal constitutional symptoms. There is complete resolution of lung nodules.

3. Discussion {#sec3}
=============

The JAK-signal transducer and activator of transcription (STAT) pathway plays a critical role in host defenses and cell mediated immunity. Use of ruxolitinib in patients with myelofibrosis can cause inhibition of the JAK-STAT signaling, thus leading to depressed T helper cell type 1 response and a reduction of multiple cytokine production including IFN-*γ* and TNF-*α*. T-Inflammatory cytokines, interferon-gamma (IFN-*γ*), and tumor necrosis factor-*α* (TNF-*α*) have a critical role in prevention of reactivation and control of TB infection \[[@B6], [@B9]\]. TNF-*α* plays a crucial role in T cell function, macrophage activation, and granuloma formation. This poses a threat for reactivation or dissemination of infections, particularly atypical bacterial, mycobacterial, fungal, and viral infections \[[@B17]\].

According to the World Health Organization, nearly one-third of the population has asymptomatic or latent tuberculosis. Less than 10% of these latent tuberculosis cases reactivate, but these cases account for nearly 80% of active tuberculosis cases. The overall incidence of tuberculosis is decreasing worldwide, but it remains a concern in patients receiving biologics such as TNF-*α* inhibitors, interleukin antagonists, and JAK inhibitors.

Eight cases of TB after ruxolitinib use in patients have been previously reported in literature ([Table 1](#tab1){ref-type="table"}) \[[@B5]--[@B7], [@B9]--[@B12], [@B18]\]. Dissemination of TB was reported in five of these cases \[[@B5], [@B7], [@B9], [@B10], [@B12]\], while the remaining two cases reported were of reactivation pulmonary TB \[[@B6]\] and extrapulmonary TB \[[@B11]\]. Therapy with ruxolitinib was withheld, and standard four-drug ATT was given in all eight cases except one \[[@B5]\]. Due to a relapse of MF syndromes, ruxolitinib therapy was reinitiated with success by Palandri et al. and Hopman et al. \[[@B9], [@B11]\]. Duration of treatment varied from 6 months \[[@B11]\] to 12 months in cases with disseminated TB \[[@B5], [@B9], [@B12]\]. At the completion of standard ATT, Palandri et al. chose to maintain long-term prophylaxis with isoniazid with no evidence of subsequent TB reactivation \[[@B11]\]. More recently, Branco et al. recently described a case of disseminated TB, occurring in a ruxolitinib treated patient, where ruxolitinib therapy was maintained while patient received rifampin \[[@B5]\].

Based on our experience, before initiating treatment with ruxolitinib, we recommend TB screening with MTB QuantiFERON test especially for patients from TB endemic areas or with prior history of TB exposure. If latent TB is diagnosed, treatment for latent TB per Infectious Disease Society of America guidelines should be considered before starting treatment with ruxolitinib \[[@B19]\].
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![CT scan of chest showing diffuse lung nodules bilaterally, left sided effusion, and mediastinal adenopathy.](CRIHEM2016-2389038.001){#fig1}

![Supraclavicular lymph node (hematoxylin and eosin stain, 20x) with partially effaced architecture and necrotizing granulomatous inflammation (arrow heads). Focal extramedullary hematopoiesis was also present. The arrow in the inset indicates an acid-fast organism (AFB stain, 1,000x).](CRIHEM2016-2389038.002){#fig2}

![Supraclavicular lymph node (hematoxylin and eosin stain, 500x) with focal areas of extramedullary hematopoiesis, including megakaryocytes (yellow arrow). The inset (CD61 immunohistochemistry, 500x) highlights frequent atypical megakaryocytes (brown) staining positive for CD61 (a platelet and megakaryocytes marker), consistent with the underlying diagnosis of primary myelofibrosis.](CRIHEM2016-2389038.003){#fig3}

###### 

Summary of cases of *Mycobacterium tuberculosis* after receipt of ruxolitinib described in the literature.

                                                                Case 1                                       Case 2                                   Case 3            Case 4            Case 5                     Case 6                                             Case 7
  ------------------------------------------------------------- -------------------------------------------- ---------------------------------------- ----------------- ----------------- -------------------------- -------------------------------------------------- -----------------
  Age (y)/sex                                                   78/F                                         78/F                                     72/M              68/M              82/M                       65/F                                               62/M
                                                                                                                                                                                                                                                                        
  Infection                                                     Disseminated TB                              Disseminated TB                          Miliary TB        Pulmonary TB      Reactivated pulmonary TB   Extrapulmonary TB                                  Disseminated TB
                                                                                                                                                                                                                                                                        
  Timing of infection after start of ruxolitinib                1.5 years                                    Unspecified                              5 months          4 weeks           2 months                   4 months                                           7 weeks
                                                                                                                                                                                                                                                                        
  Treatment of infection                                        ATT                                          ATT                                      ATT               ATT               ATT                        ATT                                                ATT
                                                                                                                                                                                                                                                                        
  Resolution of infection after treatment                                                                    Yes                                      No                No                Yes                        Yes                                                Yes
                                                                                                                                                                                                                                                                        
  Ruxolitinib therapy after diagnosis of infection              Continued                                    Discontinued at diagnosis of infection   Discontinued      Discontinued      Discontinued               Discontinued                                       Discontinued
                                                                                                                                                                                                                                                                        
  Reintroduction of ruxolitinib during treatment of infection   Ruxolitinib continued without interruption   No                                       No                No                No                         Restarted after 6 months of ATT                    Restarted
                                                                                                                                                                                                                                                                        
  Ruxolitinib resumed after completion of infection treatment   Continued without interruption               Unspecified                              No                No                Unspecified                Ruxolitinib continued with isoniazid prophylaxis   Continued
                                                                                                                                                                                                                                                                        
  Relapse of infection                                          No                                           No                                       N/A               N/A               No                         No                                                 No
                                                                                                                                                                                                                                                                        
  Outcome                                                       Alive                                        Alive                                    Died              Died              Alive                      Alive                                              Alive
                                                                                                                                                                                                                                                                        
  Year/reference                                                2016/\[[@B5]\]                               2015/\[[@B12]\]                          2015/\[[@B10]\]   2015/\[[@B10]\]   2015/\[[@B6]\]             2015/\[[@B11]\]                                    2014/\[[@B9]\]
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